Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis

[PR Newswire] – TARRYTOWN, N.Y. and PARIS, Oct. 20, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed . . . → Read More: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis Similar Articles: Stock Update (NASDAQ:REGN): LinkedIn, YY Among 5 Stocks With Top Fundamentals Stock Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) Company Update (NASDAQ:REGN): Regeneron Announces Upcoming 2014 Investor Conference Presentations